Navigation Links
Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.  This trial, known as STEPWISE (a randomized, double-blind, multi-center STudy comparing cross-linkEd Polyelectrolyte (CLP) WIth placebo in HF SubjEcts), is designed to evaluate the safety and efficacy of CLP-1001 in addressing signs and symptoms of fluid overload in patients with congestive heart failure (HF).  CLP-1001 is a novel, non-absorbed oral polymer that acts by binding to and removing excess sodium and fluid in the GI tract independently of the kidneys.

"The objective of the STEPWISE trial is to further understand the magnitude of the effect of CLP-1001 on key measures and clinical endpoints of heart failure-induced congestion compared to current standard of care," said Howard C. Dittrich , M.D., F.A.C.C., Chief Medical Officer of Sorbent.  "Fluid overload in heart failure patients contributes importantly to hospitalizations -- including re-hospitalizations -- slows in-patient recovery, and results in poor quality of life and physical limitations.  Based on the positive clinical benefits observed in our Phase 2a clinical trial, we look forward to advancing CLP-1001 through late-stage registration studies."   

STEPWISE is a double-blind, randomized, placebo-controlled, multicenter, study designed to evaluate CLP-1001 in patients with heart failure.  Approximately 250 patients on stable, optimized, guideline heart failure therapy that have signs and symptoms of current fluid overload after a recent HF-related hospitalization will be randomized to receive 15 grams of CLP-1001 or placebo.  The primary objective of this trial is to assess the change from baseline to eight weeks across sever
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
3. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
4. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015  PTC Therapeutics, Inc. (NASDAQ: ... of its first-ever global awards program, the STRIVE ... designed to aid nonprofit organizations that are committed ... The announcement is made as the global DMD ... Day on Monday, September 7, 2015. ...
(Date:9/4/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Rodman & Renshaw 17 th Annual Global Investment ... New York City .  Dr. Michael Berelowitz ... on September 9, 2015. Presentation Details: ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Promising Clinical Activity in Patients with ... Difficult-to-Treat Cancers -, ... (Nasdaq: SNSS ) presented data from three clinical,trials of ... Foundation Symposium held in New York on November 4-8.,Data previously ...
... Inc.,(Nasdaq: MEDX ) today announced that it ... from its licensing partner, Centocor R&D Inc., for,the ... 95, a fully human antibody,targeting the integrin receptors ... human antibody was generated using Medarex,s,UltiMAb(R) technology. Medarex ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 2Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 3Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 4Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 5Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2
(Date:9/4/2015)... ... ... consumers are looking for a quick and convenient way to produce a hot remedy for ... provide a quick and simple way to brew a hot cup of cold remedy when ... result, they enhance comfort and health. The invention features a novel design that is lightweight, ...
(Date:9/4/2015)... Washington (PRWEB) , ... September 04, 2015 , ... ... design and development of its first neighborhood created specifically for adults with intellectual, ... in the Phoenix Metro area and feature 30 cottage or “pocket” homes. In ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... a Labor Day offer that cannot be passed up. FiltersFast.com, will ship ... necessary air and water filtration product replacements. Take advantage of this promotion now ...
(Date:9/3/2015)... Fullerton, Calif. (PRWEB) , ... September 03, 2015 , ... ... in Fullerton, where innovative medicine is the norm not the exception. , St. Jude ... and the American Heart Association/American Stroke Association, making it one of only 10 hospitals ...
(Date:9/3/2015)... ... 03, 2015 , ... E-Volve Health, an Elliot Health System ... organization, to provide electronic medical record (EMR) consulting services to Amerinet clients running ... negotiated pricing on E-Volve Health’s Epic EMR consulting, custom training and support services. ...
Breaking Medicine News(10 mins):Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2
... company PreMD Inc. (TSX: PMD; PREMF.pk) today announced the ... Corporation. Mr. Davis has been a director of PreMD ... sincere thanks to Paul for his contribution to PreMD," ... Inc.PreMD Inc. has rapid, non-invasive tests for the early ...
... drugs could prevent 2 of 10 deaths expected in ... 26 (HealthDay News) -- Blood pressure-lowering drugs should be ... them from major cardiovascular events and death, say researchers ... Those studies assessed the effects of lowering blood pressure ...
... , Montreal, February 26, 2009 A team ... and its affiliated Maisonneuve-Rosemont Hospital Research Centre will be honoured ... prestigious award in the field of hip surgery. The award ... , As North American pioneers in the development of new ...
... that has discovered a new gene whose mutations cause ... sclerosis) is part of a national study led by ... study reported in Science today (Feb. 27) ... neurological disorder, said Teepu Siddique, M.D., Les Turner ALS ...
... 96% In First Full Year As A Public CompanyCARLSBAD, ... GXDX ), a specialized laboratory services provider, today reported ... 2008, which includes a $2.2 million benefit from changes ... is an increase of approximately 83.0% over revenues of ...
... fall and winter infants more likely to develop asthma ... high levels of pollen and mold in their first few ... a possible early symptom of asthma, say U.S. researchers. , ... California,s Salinas Valley, and found that children born in high ...
Cached Medicine News:Health News:PreMD Announces Resignation of Director 2Health News:Lowering BP in Dialysis Cases Cuts Heart Risks 2Health News:Team of orthopedic surgeons and kinesiologists win hippest of awards 2Health News:Researchers identify ALS gene mutation 2Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 2Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 3Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 4Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 5Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 6Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 7Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 8Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 9Health News:Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009 10Health News:Babies Born in High Pollen Months at Wheezing Risk 2
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
Medicine Products: